Analysis of urinary exosomal metabolites identifies cardiovascular risk signatures with added value to urine analysis

Abstract

Background Subclinical atherosclerosis may result in fatal cardiovascular (CV) events, but the underlying mechanisms and molecular players leading to disease are not entirely understood. Thus, novel approaches capable of identifying the factors involved in pathological progression and providing a better understanding of the subjacent mechanisms are needed. Extracellular vesicles (EVs) have been shown to have numerous biological functions, and their metabolome has recently generated interest as a source of novel biomarkers. The metabolic content of the exosomes has been so far unexplored in cardiovascular disease (CVD), and here, we developed an analytical strategy aimed at probing urinary exosomal metabolite content and its association to CV risk. Results Direct analysis of the exosomes without metabolite extraction was evaluated by high-resolution magic angle spinning (1H HR-MAS). Other two methodologies for the analysis of exosomal metabolites by 1H NMR were set up, based on methanol or organic solvents sequential extraction. The three methods were compared in terms of the number of detected signals and signal to noise ratio (S/N). The methanol method was applied to identify altered metabolites in the urinary exosomes of subjects with programmed coronary artery by-pass grafting (CABG) versus a control group. Target mass spectrometry (MS) was also performed for differential analysis. The clinical performance of exosomal metabolites of interest in CVD was investigated, and the added value of the exosomes compared to urine analysis was evaluated. Based on S/N ratio, simplicity, reproducibility, and quality of the spectrum, the methanol method was chosen for the study in CVD. A cardiometabolic signature composed by 4-aminohippuric acid, N-1-methylnicotinamide, and citric acid was identified in urinary exosomes. Directly in urine, 4-aminohippuric acid and citric acid do not show variation between groups and changes in N-1-methylnicotinamide are less pronounced, proving the added value of exosomes. Conclusions We set up a novel methodology to analyze metabolic alterations in urinary exosomes and identified a cardiometabolic signature in these microvesicles. This study constitutes the first evidence of a role for the exosomal metabolism in CVD and demonstrates the possibility to evaluate the urinary exosomal metabolic content by NMR and MS.

Tumor-Derived Extracellular Vesicles Regulate Cancer Progression in the Tumor Microenvironment

“…As a means of communication between tumor cells and the microenvironment, EVs play an essential role in remodeling the local microenvironment ( Milane et al, 2015 ). Numerous studies have revealed that EVs released by tumor cells contain a variety of biomolecular components, including lipids, proteins and nucleic acids ( Taylor et al, 2011 ; Mathivanan et al, 2012 ; Agudiez et al, 2020 ). Especially, those nucleic acids components such as miRNAs and lncRNAs may mediate the formation of a protumoral or an anti-tumoral soil in the microenvironment, thereby influencing tumor progression.…”

Metabolomics of Extracellular Vesicles: A Future Promise of Multiple Clinical Applications

“… 80 Urine-derived EVs have also been applied to investigate the variation in cardiovascular disease, which identifies novel cardiovascular risk signatures. 81 …”

“…80 Urine-derived EVs have also been applied to investigate the variation in cardiovascular disease, which identifies novel cardiovascular risk signatures. 81 For respiratory diseases, EVs from bronchoalveolar lavage fluid are widely used for purposes, such as comparing lipid between asthmatic patients and healthy people. 49 Brain tissue-derived EVs include samples collected in chromochromic leukodystrophy (MLD) and control mice.…”

Circulating Extracellular Vesicles As Biomarkers and Drug Delivery Vehicles in Cardiovascular Diseases

“…EVs can carry ceramides, sphingomyelin, lysophosphatidylcholine, arachidonic acid, and other fatty acids, cholesterol, prostaglandins, leukotrienes, and active lipolytic enzymes (such as phospholipase A2) on their membrane or within their lumen, and their lipid composition can be modified by in vitro manipulation [ 18 ]. Circulating EVs were enriched with different sphingolipid species (ceramides, dihydroceramides, and sphingomyelins) in patients with STEMI, and lipid levels correlated with cardiac troponin, leucocyte count, and lower left ventricular ejection fraction [ 123 ].…”